header logo image


Page 110«..1020..109110111112..120130..»

NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck…

December 28th, 2022 12:11 am

PARIS and CAMBRIDGE, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the first patient in the United States has been randomized in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma (“LA-HNSCC”) who are ineligible for platinum-based chemotherapy. NBTXR3 activated by radiotherapy will be evaluated alone or in combination with cetuximab. NBTXR3 is a potentially first-in-class radioenhancer with broad application across solid tumors, with prioritized focus in head and neck cancer.

Go here to read the rest:
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck...

Read More...

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors

December 28th, 2022 12:11 am

STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that the Company has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for nirogacestat, an investigational gamma secretase inhibitor, for the treatment of adults with desmoid tumors.

See the original post here:
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors

Read More...

Catalyst Biosciences Completes First Steps in Reverse Merger Plan

December 28th, 2022 12:11 am

Acquires F351, a Phase 3 Drug to Treat Fibrosis

Read more:
Catalyst Biosciences Completes First Steps in Reverse Merger Plan

Read More...

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

December 28th, 2022 12:11 am

NEW YORK, Dec. 27, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD/LFMDP), a leading direct-to-patient telehealth company, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.

Visit link:
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

Read More...

TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023

December 28th, 2022 12:11 am

Initial $3.5M Funding Maintains Cash Runway of Mid-2023 Initial $3.5M Funding Maintains Cash Runway of Mid-2023

View post:
TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023

Read More...

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders

December 28th, 2022 12:11 am

New FDA-approved formulation for patients living with urea cycle disorders

See the original post here:
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders

Read More...

Transactions in connection with share buy-back program

December 28th, 2022 12:11 am

Company announcement no. 31 - 2227 December 2022

Read more here:
Transactions in connection with share buy-back program

Read More...

Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland

December 28th, 2022 12:11 am

PRESS RELEASE

Read this article:
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland

Read More...

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

December 28th, 2022 12:11 am

-- On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 -- -- Received remaining $25 million investment under previously announced private placement financing --ARLINGTON, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application for the company’s lead product candidate, KPI-012, a human mesenchymal stem cell secretome (MSC-S), initially in development for the treatment of persistent corneal epithelial defect (PCED).

Continue reading here:
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Read More...

Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

December 28th, 2022 12:11 am

SALT LAKE CITY, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company today announced topline study results from its Phase 2 investigational trial with CNM-ZnAg, an ionic solution of zinc and silver, for the treatment of non-hospitalized acutely symptomatic participants infected with COVID-19.

Original post:
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

Read More...

Seer to Present at the J.P. Morgan 41st Annual Health Care Conference

December 28th, 2022 12:11 am

REDWOOD CITY, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.

Read more:
Seer to Present at the J.P. Morgan 41st Annual Health Care Conference

Read More...

Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 28th, 2022 12:11 am

SEATTLE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

See the rest here:
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference

Read More...

Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics

December 28th, 2022 12:11 am

-- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors -- -- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors --

Read more:
Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics

Read More...

Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) – Interim Results for the Six Months Ended 30 June 2022

December 28th, 2022 12:11 am

Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need

More:
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022

Read More...

Buccal Fat Pad as a Potential Source of Stem Cells for Bone … – Hindawi

December 20th, 2022 12:37 am

Adipose tissues hold great promise in bone tissue engineering since they are available in large quantities as a waste material. The buccal fat pad (BFP) is a specialized adipose tissue that is easy to harvest and contains a rich blood supply, and its harvesting causes low complications for patients. This review focuses on the characteristics and osteogenic capability of stem cells derived from BFP as a valuable cell source for bone tissue engineering. An electronic search was performed on all in vitro and in vivo studies that used stem cells from BFP for the purpose of bone tissue engineering from 2010 until 2016. This review was organized according to the PRISMA statement. Adipose-derived stem cells derived from BFP (BFPSCs) were compared with adipose tissues from other parts of the body (AdSCs). Moreover, the osteogenic capability of dedifferentiated fat cells (DFAT) derived from BFP (BFP-DFAT) has been reported in comparison with BFPSCs. BFP is an easily accessible source of stem cells that can be obtained via the oral cavity without injury to the external body surface. Comparing BFPSCs with AdSCs indicated similar cell yield, morphology, and multilineage differentiation. However, BFPSCs proliferate faster and are more prone to producing colonies than AdSCs.

Mesenchymal stem cells (MSCs) derived from bone marrow aspirates have been frequently used as a cell source in bone tissue engineering [1]. However, several problems are associated with the clinical application of bone marrow stem cells (BMSCs) [1]. The harvesting procedure is associated with pain and discomfort for patients, and their differentiation capability is dependent on the donor age [2].

Adipose tissues have been introduced as a promising source of MSCs that can be obtained with minimal discomfort for patients, since subcutaneous adipose tissues are usually discarded after aesthetic surgical procedures. In addition, several studies have shown that the cell yield from adipose tissues is 100 to 500 times greater than that from bone marrow aspirates [35]. Therefore, minimally invasive procedures can be used to obtain a high number of MSCs with similar multilineage capabilities [68]. However, not all patients undergo liposuction, and fat distribution is dependent on body weight.

Recently, Farre-Guasch et al. isolated adipose-derived stem cells (AdSCs) from a mass of fatty tissue in the oral cavity called Bichats fat pad or the buccal fat pad (BFP). These cells have a similar phenotype to AdSCs from abdominal subcutaneous adipose tissue [9]. Under appropriate conditions, AdSCs derived from BFP (BFPSCs) have been shown to differentiate into chondrocytes, osteoblasts, or adipocytes in vitro [9]. Moreover, Shiraishi et al. reported that BFPSCs can form engineered bone in the back subcutaneous pockets of nude mice [10]. Khojasteh and Sadeghi recently used BFPSCs in conjunction with iliac bone block grafts and showed an increase in the amount of new bone formation and a decrease in secondary bone resorption in extensively atrophic jaws [11].

In addition to BFPSCs, dedifferentiated fat cells (DFAT) derived from BFP (BFP-DFAT) can be produced from mature adipocytes by a convenient method called ceiling culture technique. These cells possess high potential for regeneration of the bone and periodontal tissues [10, 12]. Therefore, BFP could be considered as a potential cell source for bone engineering in oral and craniofacial areas since it is easy to harvest and provides a proper quantity of tissue for cell isolation. The present study reviews research on the characteristics and osteogenic capability of stem cells derived from BFP as a promising cell source for bone tissue engineering in the oral and craniofacial regions.

This systematic review has been organized according to the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement.

This review included all in vitro and in vivo studies that used BFPSCs and BFP-DFAT cells from human or animal sources for bone regeneration. Abstracts, reviews, letters, and theses were excluded. Studies were excluded if they used the BFP flap or mass (i.e., without cells) and if they did not focus on bone formation or differentiation towards the osteoblast lineage.

The PubMed/MEDLINE, EMBASE, Web of Science, and Cochrane electronic databases were searched for relevant studies published between January 2010 and November 2016. No limitation in language was applied in the search process. The following search terms were used, in which mh represents the MeSH terms and tiab represents the title or abstract: (buccal fat pad (mh) or buccal fat pad (tiab) or BFP (mh) or BFP (tiab)) and (cell (tiab) or stem cell (tiab) or tissue engineering (tiab) or adipose tissue stem cell (tiab)). Additionally, a manual search was also performed in the following journals in the given time periods: Stem Cells, Stem Cell Research, Journal of Stem Cells, and Regenerative Medicine.

Initial screening of titles and abstracts was carried out based on the inclusion and exclusion criteria, and full texts of all eligible studies were obtained. Two independent reviewers extracted and processed data for analysis according to the predefined eligibility criteria. In case of any disagreement, agreement was obtained following a discussion with the third reviewer. The fourth and fifth reviewers contributed to discussion section.

The results and data were extracted from the full text of the articles. The studies were then classified and summarized as in vitro and in vivo studies. In in vitro studies, the following outcomes were assessed: alkaline phosphate (ALP) activity, alizarin red staining, osteocalcin (OCN) content, and gene expression using reverse transcription polymerase chain reaction (RT-PCR). The results of histological evaluation and radiographic evaluation were also assessed for in vivo studies. Since the focus of the present review is the BFP stem cells derived from both human and animal origins, the sources of cells were also identified (Tables 1 and 2).

As illustrated in the PRISMA flow diagram in Figure 1, the initial search retrieved a total of 406 studies. Following the initial screening of titles and abstracts, 16 studies were selected for final screening of the full texts. A total of 10 articles met the inclusion criteria and were included in the analysis (Figure 1). Of these 10 studies, seven were conducted in vitro [9, 1217], and the other three were conducted both in vitro and in vivo [10, 11, 18].

All in vitro studies except for two compared BFPSCs with other cell sources, including AdSCs, BMSCs, unrestricted somatic stem cells (USSCs), and subcutaneous adipose stem cells (SC-AdSCs) [9, 1214, 17]. All studies derived stem cells from human volunteers except for a study by Niada et al., where BFPSCs were derived from swine and compared to SC-AdSCs [13]. Three of the 10 studies focused on BFP-DFAT cells [1416]. One experiment focused on the size of DFAT cells and compared small cells (<40m) with large cells (40100m) based on the characteristics for MSCs [16].

Three studies reported in vivo results in addition to in vitro assessment [10, 11, 18]. Two studies reported bone formation results after the application of BFPSCs in animal models [10, 11], and one study performed human bone regeneration. Shiraishi et al. used recombinant human bone morphogenetic protein 2 (rhBMP2) with cells [10], and Nagasaki et al. combined low-intensity pulsed ultrasound and nanohydroxyapatite scaffolds for transplanting BFPSCs into the calvarial defects of mice [18]. Khojasteh and Sadeghi loaded BFPSCs on an allograft and implanted that in combination with autogenous iliac bone in severely atrophic jaws [11].

Data extracted on the characteristics of BFPSCs and SC-AdSCs are compared in Table 3. Tissue volume, number of cells, collagen deposition, ALP activity, and glycosaminoglycan (GAG) content have been shown to be greater in SC-AdSCs, but cell proliferation, morphology, size, adipogenic differentiation, and expression of MSCs markers are similar. In addition, unlike SC-AdSCs, BFPSCs are capable of producing colony-forming units [9, 12, 13].

Adipose tissue contains two different fractions: (1) stromal vascular fraction (SVF), which includes MSCs (preadipocytes), fibroblasts, and erythrocytes and (2) mature adipocytes [9]. AdSCs isolated from the SVF were considered to be the key MSCs within this tissue and can be induced towards adipocytes, osteocytes, chondrocytes, myocytes, and neurons [1921]. Since the SVF has a complex structure and cellular composition, AdSCs derived from SVF, particularly in early passages, are heterogeneous populations composed of cells with various characteristics and behaviors [9, 2227].

Mature adipocytes are another abundant type of cells in fat tissue, and they have also shown dynamic plasticity to be converted into DFAT cells by a ceiling culture technique [2830]. Unlike terminally differentiated adipocytes, DFAT cells have significant and steady proliferation capability [3033]. In contrast to AdSCs, DFAT cells have been shown to have a more homogeneous cell population [15, 16, 30]. In addition, a greater number of DFAT cells can be produced from a given amount of fat tissue [34, 35].

The cellular nature and differentiation stage of DFAT cells have not been fully clarified. However, several studies have suggested that DFAT cells are in the late stage of the differentiation process and classified them into preadipocytes [36, 37]. Similar to preadipocytes, DFAT cells could be redifferentiated into lipid-filled adipocytes under proper induction [29, 30, 38, 39]. Evaluations of stem cell-related markers and multilineage differentiation assays (i.e., adipogenesis, chondrogenesis, and osteogenesis) have also suggested that DFAT cells are similar to AdSCs [30, 38]. Poloni et al. also produced neurospheres from DFAT cells [40, 41], indicating that their multipotency might extend beyond the mesodermal lineages [40, 42]. Kishimoto et al. demonstrated that DFAT cells also showed proliferation and differentiation towards osteoblasts when they were cultured on self-assembling peptide or titanium fiber mesh scaffolds [14, 43, 44]. These findings highlight the hypothesis that DFAT cells are multipotent cells and have potential for use in tissue engineering.

One major goal of tissue engineering is to find a source of stem cells that can provide an adequate number for clinical application with minimal morbidity, maximal proliferation rate, and high differentiation potential [9, 17]. The BFP in the oral cavity is a mass of specialized fatty tissue that is distinct from subcutaneous fat and is located on either sides of the face between the buccinator muscle and other superficial muscles (Figure 2(a)) [4548]. The BFP has a rich vascular supply [4952] and can be harvested easily by an intraoral flap with minimal discomfort and complications for patients (Figure 2(b)) [9, 5254]. In addition, BFP is a discarded tissue in plastic surgery for cheek reduction [13]. Furthermore, it is routinely administered in the treatment of the bone, periodontal defects [49, 5559], congenital oroantral diseases, oronasal diseases [60], congenital cleft palate repair [61], oral submucous fibrosis [62, 63], intraoral malignant defects [64], and cheek mucosa defects [65].

Another advantage of BFP over subcutaneous fat is that its size appears to be similar among different people, independent of body weight and fat distribution [66]. Patients with little subcutaneous fat have BFP with normal weight and volume [9]. Recent studies have shown that both AdSCs [9, 10] and DFAT cells [14] isolated from human BFP (i.e., BFPSCs and BFP-DFAT cells) are similar to SC-AdSCs and possess high potential for regeneration of the bone and periodontal tissues [10, 12]. These properties may make the BFP a desirable cell source for tissue engineering and cell isolation.

Since BFP is easily accessible via the oral cavity without injury to the external body surface, several research groups have recently evaluated the behavior of isolated AdSCs from the BFP as a proper source of adult cells for clinical applications [13].

BFPSCs have been reported to remain in a quiescent state during 24 days of culture and showed spindle-shaped morphology similar to AdSCs, BMSCs, and USSCs [17]. Afterward, they began to multiply rapidly, formed a monolayer of large flat cells, and exhibited a more fibroblast-like morphology characteristic of AdSCs [9].

Cell surface markers on BFPSCs were characterized by immunofluorescence combined with flow cytometric analysis [10, 12, 67]. BFPSCs expressed MSC-defined markers, including CD73, CD90, and CD29, whereas they did not express lymphocyte or leucocyte antigens [12] and hematopoietic markers such as CD14, CD31, CD34 [9, 12], CD45 [10], CD19, and HLADR [9]. In addition, Traktuev et al. reported that BFPSCs showed some expression of CD34, which is characteristic of fresh AdSCs [68]. However, this marker declined with passage in AdSCs [9]. CD34+ cells have been shown to stimulate angiogenesis, and they are involved in neovascularization processes that facilitate healing of damaged tissues [69, 70].

Similar to other AdSCs, freshly isolated BFPSCs lack expression of CD105, but expression of this marker increases rapidly after seeding [20, 71]. AdSCs also usually lack expression of CD146, a characteristic marker of endothelial cells as well as vascular smooth muscle cells. However, Farr-Guasch et al. found a small population of CD146 cells in the first passages of BFPSCs [9]. The presence of this CD146-contaminated population, as well as the presence of CD34 cells, might be due to the highly enriched blood vessel supply in BFP [72]. This could be related to the excellent wound-healing properties of BFP as a pedicled graft in oral surgery for treatment of oroantral communications [55, 73], maxillary defects [51], oral submucous fibrosis [74], and vocal cord defects [75].

Several researchers have shown that BFPSCs are multipotent and differentiate towards osteogenic, adipogenic, and chondrogenic lineages in the presence of inductive stimuli [9, 12, 76, 77]. Broccaioli et al. showed that after 14 days of osteogenic induction, BFPSCs showed a significant upregulation of two specific markers, ALP activity and collagen deposition [12]. Farr-Guasch et al. also showed that after 1 week of culture in osteogenic medium, BFPSCs changed their morphology from spindle shaped to more polygon shaped, which was accompanied by an increase in ALP activity [9]. They reported that BFPSCs cultured in osteogenic medium showed osteocalcin expression. In addition, Niada et al. demonstrated the expression of core-binding factor alpha subunit 1 (CBFA1) and osteonectin. They also showed that compared with undifferentiated cells, osteogenic-differentiated BFPSCs derived from swine significantly increased the production of bone-specific markers, such as collagen, calcified extracellular matrix (ECM), ALP, and osteonectin [13].

After adipogenic induction of BFPSCs, the classic fibroblast-like shape of human AdSCs changed, and BFPSC populations showed intracellular lipid vacuoles that increased in size and number during culture [9, 12, 13]. Farr-Guasch et al. showed increased expression levels of a specific adipocyte marker during culture, peroxisome-proliferating receptor gamma (PPAR), reaching approximately four times higher induction compared to those of undifferentiated BFPSCs [9]. Some studies also showed that BFPSCs synthesized cartilage matrix molecules and produced an extracellular matrix characteristic for chondrocytes when grown in chondrogenic medium. Farr-Guasch et al. observed that after five days of chondrogenic induction, BFPSC morphology became more spheroid shaped [9]. Immunohistochemistry in differentiated BFPSCs indicated Toluidine blue-stained nodules indicative of a proteoglycan matrix characteristic for cartilage and expression of collagen II, a marker believed to be specific for articular cartilage. In addition, increased expression of the master chondrogenic factor, SOX9, was observed in BFPSCs, followed by decreased expression of the adipogenic marker PPAR when they induced towards the chondroblast lineage [9]. Niada et al. also observed GAG content in chondrogenic differentiated BFPSCs following three weeks of induction [13].

It is well known that rhBMP-2 enhances osteogenic differentiation of BMSCs [78]. However, it has been suggested that rhBMP-2 may not influence the osteogenic differentiation of AdSCs [25, 79]. Shiraishi et al. analyzed the capability of rhBMP-2 to induce osteogenesis on BFPSCs cultured in different culture conditions (i.e., osteoinductive reagents (OS), rhBMP2 (BMP), and the combination of BMP and OS (BMP-OS)) [10]. Their results indicated that rhBMP-2 strongly induced the osteogenic differentiation of human BFPSCs. After 1014 days in culture, rhBMP-2 treatments (BMP and BMP-OS) induced distinct and substantial calcified-nodule formation and the expression of osteogenic markers in BFPSCs. In addition, they showed that BFPSCs pretreated with BMP-OS generated abundant bone tissue upon in vivo transplantation to the back subcutaneous pockets of nude mice [10].

Amelogenin (AM) is the most abundant enamel matrix protein, and it is favored for the repair of periodontal defects. Broccaioli et al. indicated that osteogenic differentiation of BFPSCs is specifically induced and upregulated by AM with a synergic effect with other osteoinductive factors [12], which was also reported for bone marrow MSCs [8082]. This effect is more evident for BFPSCs than for SC-AdSCs, possibly due to the natural localization of BFPSCs, which could make them more prone to responding to stimuli naturally secreted in the same area of the body [12].

Several research groups compared AdSCs derived from different areas of the body and evaluated their behavior in vitro to identify a convenient source for future preclinical studies (Table 1).

Several studies showed that the number of SC-AdSCs is similar to the number of BFPSCs, despite the different amounts of raw adipose tissues [12, 32]. However, Farr-Guasch et al. observed that the number of BFPSCs was two times higher than the number of SC-AdSCs after one week of culture. They admitted that this difference might be due to the differences in age, intrinsic characteristics of the patients, or particular properties of the adipose source [9].

Several studies reported that both BFPSCs and SC-AdSCs showed similar morphology (fibroblast-like morphology) [9, 10, 13]. However, Broccaioli et al. observed that BFPSCs appeared slightly smaller and rounder than SC-AdSCs [12].

Both types of cells similarly expressed defined MSC markers. Farr-Guasch et al. reported that the expression of CD34 was much higher in BFPSCs than in SC-AdSCs [9]. They also found the expression of CD146 in a small population of CD146 cells in the first passages of BFPSCs, but not in SC-AdSCs.

Broccaioli et al. showed that SC-AdSCs proliferated faster than BFPSCs, with an average doubling time of 73h compared to 126h. This was also confirmed through a viability test, in which MTT incorporation by SC-AdSCs was mildly higher than that by BFPSCs [12]. However, similar doubling times were observed for BFPSCs and SC-AdSCs derived from swine [13].

Broccaioli et al. showed that BFPSCs were more prone to producing colonies than SC-AdSCs [12]. Interestingly, BFPSCs showed a significant increase in colony formation in late passages (from passages 7 to 9), suggesting a delayed selection of progenitor cells [12]. However, no significant difference has been observed between colony formation of porcine SC-AdSCs and BFPSCs from passages 1 to 4 [13].

Several researchers showed that both cell types are multipotent and differentiate into different cell lineages in the presence of inductive stimuli [13, 76, 77]. Broccaioli et al. showed that after 14 days of osteogenic induction, both BFPSCs and SC-AdSCs showed a significant upregulation of two specific markers, ALP activity, and collagen deposition [12]. Niada et al. also showed that osteogenic-differentiated SC-AdSCs and BFPSCs derived from swine significantly increased the production of bone-specific markers compared with undifferentiated cells, such as collagen, calcified ECM, ALP, and osteonectin. The greatest difference was observed in the collagen level of 7-day-osteoinduced BFPSCs, which was 7 times higher than that of osteoinduced SC-AdSCs [13]. Similar capabilities in adipogenic and chondrogenic differentiation have been observed in both BFPSCs and SC-AdSCs [9, 13, 76].

Considering possible clinical applications, Broccaioli et al. studied the ability of BFPSCs and SC-AdSCs to grow in a medium supplemented with human serum [12]. Both populations were cultured in the presence of autologous serum (HAS) or heterologous serum (HHS), and their growth was compared to that of cells maintained in standard conditions (FBS). No differences in morphology were observed. In all the growth conditions, the AdSC populations maintained the fibroblast-like shape, and HAS induced a prompt increase in both BFPSC and SC-ASC numbers compared to other serums within 7 days. They noticed that the presence of human serum enhanced the proliferation rate of both cells types. This effect has not been previously observed in AdSCs, but similar heterogeneity in the response to autologous serum has also been described for BMSCs [26, 8385] and could be explained by the differences in serum from the donors. Growing AdSCs in the presence of autologous serum could be a convenient and safe procedure in future cellular therapy, which would eliminate concerns about contact with animal proteins [12].

Several research groups evaluated the behaviors of BFPSCs (e.g., adhesion, growth, and differentiation) on natural and synthetic biomaterials and compared them with other stem cells. Broccaioli et al. showed that both SC-AdSCs and BFPSCs can adhere to the autologous alveolar bone and periodontal ligament [12]. Moreover, they reported that these cells efficiently adhered to a collagen membrane. However, BFPSCs have not shown tight bonding to suture filaments of polyglycolic acid compared to AdSCs [12].

Niada et al. evaluated the ability of porcine AdSCs derived from SC and BFP to grow and differentiate on two synthetic scaffolds: titanium and plasma-treated silicon carbide [13]. They showed that both porcine AdSCs adhered and differentiated on these scaffolds. Ardeshirylajimi et al. assessed the osteogenic differentiation potential of MSCs on surface-modified poly(L-lactide) acid (PLLA) nanofibers. The MSCs were derived from four different sites: BFP, the bone marrow, subcutaneous adipose tissue, and unrestricted somatic stem cells [17]. No significant difference was observed in the proliferation rates. All four types of stem cells were demonstrated to differentiate efficiently into osteoblast-like cells on nanofibrous scaffolds in osteogenic medium. The highest ALP activity and calcium content were observed in BMSCs cultured on PLLA. Interestingly, BFPSCs resembled BMSCs in both ALP and calcium content. In addition, the highest expression of bone-related gene expression (i.e., Runx2, osteonectin, and osteocalcin) was observed in BFPSCs and BMSCs compared to that in other stem cell types [17].

AdSCs are used extensively for tissue engineering, and various studies have reported their utility [2224]. However, AdSCs at passage 0 include contaminating endothelial cells, smooth muscle cells, and pericytes [86]. In contrast to AdSCs, mature adipocytes are the most abundant cell type in adipose tissue and have dynamic plasticity to be converted into DFAT cells [31]. Compared with ASCs, a relatively homogeneous cell population of DFAT cells has been revealed by flow cytometric analysis [31]. DFAT cells could not only redifferentiate into lipid-filled adipocytes in the same way as preadipocytes but they can also transdifferentiate into other cell types under proper conditions in vitro, including osteoblasts [14, 30, 38], chondrocytes [30], and myocytes [8790]. In vivo studies also suggested that DFAT cells could regenerate fat pads, ectopic osteoid tissue, or muscle tissue [30, 3638, 88, 90].

BFP-DFAT cells have been shown to be positive for CD90, CD105 [14], CD13, CD29, and CD44 [15] but negative for CD11b (monocyte marker), CD34 (hematopoietic progenitor cell marker), CD45 (leukocyte common antigen) [14], CD31, CD309, CD106, and alpha-smooth muscle actin [15, 30].

Kou et al. showed that after 3 weeks of osteogenic culture, the DFAT cells demonstrated limited mineralized matrix indicated by alizarin red S staining, while a relatively large portion of cells assumed a multilocular appearance and they were positive for adipose staining [15]. Previous reports confirmed the expression of osteogenic transcription factors in DFAT cells, including Runx2, osteopontin, osteorix, and osteocalcin [22, 29, 30]. However, Kou et al. showed that DFAT cells exhibited lower potential of differentiating towards osteoblasts than an adipocyte lineage [15]. This could be due to the fact that the multipotent capacity of DFAT cells is tissue specific [15].

Tsurumachi et al. divided adipocytes into two groups based on their size: those with cell diameters less than 40m (small adipocytes: S-adipocytes) and those with diameters of 40100m (large adipocytes: L-adipocytes). They investigated the influence of the adipocyte size on the dedifferentiation efficiency into DFAT cells and compared the S- and L-DFAT cells based on the characteristics for MSCs. They showed that the S-adipocytes contained more juvenile adipocytes than the L-adipocytes. The results suggested higher rates of dedifferentiation for S-DFAT cells compared to those for L-DFAT cells and that the adipocyte size is positively associated with dedifferentiation. However, more studies are needed to reveal how the cell size could influence the efficiency of mature adipocyte dedifferentiation [16].

Tsurumachi et al. conducted flow cytometry and revealed higher CD146 expression in S-DFAT cells compared to that in L-DFAT cells, although both cells showed high expression levels of CD13, CD44, CD73, CD90, and CD105 [16]. S-DFAT cells showed higher osteogenic potential in particular compared to the L-DFAT cells. Similarly, a comparison between AdSCs and DFAT cells obtained from BFP demonstrated more effective induction of osteoblasts from DFAT cells than from AdSCs [14]. S-DFAT cells also exhibited higher osteogenic potential than L-DFAT cells. The results suggested that S-DFAT cells have an advantage over L-DFAT cells and AdSCs in bone tissue engineering.

Matsumoto et al. reported that human AdSCs at passage 1 are 13.3% positive for CD11b (monocyte marker) and 12.8% positive for CD45 (leukocyte common antigen). However, human DFAT cells at passage 1 are negative for these markers, indicating greater homogenicity of DFAT cells compared with AdSCs [30]. Kishimoto et al. showed that the expression of osteoblastic differentiation markers (BAP, OCN, and calcium) in BFP-DFAT cells was more prevalent than that in BFPSCs [14]. However, they indicated that the difference in the osteoblastic differentiation ability of BFPSCs and BFP-DFAT cells was not because of the difference of purity in the cell populations [14]. The same group also reported various osteoblastic differentiation abilities between human DFAT cells derived from the submandibular and human BMSCs [91]. Gene expression of Runx2, ALP, OCN expression, and calcium deposition was higher in DFAT cells than in bone marrow MSCs. More studies are needed to come to a general conclusion regarding the osteogenic capability of BFP-DFAT.

This study has reviewed the characteristics and osteogenic capability of AdSCs derived from BFP. This source of cells was also compared with other AdSCs from other parts of the body. BFP is an easily accessible source of stem cells that can be obtained easily via the oral cavity without injury to the external body surface. Its size is similar between people and independent of body weight and fat distribution. Comparing BFPSCs with other AdSCs showed similarities in cell yield, morphology, and multilineage differentiation. However, BFP has been shown to proliferate faster and is more prone to producing colonies. Limited studies have been conducted on the osteogenic capability of BFP-DFAT cells, which makes conclusions infeasible.

The authors declare that there is no conflict of interest regarding the publication of this paper.

This research was supported by the Research Deputy, Dental School, Shahid Behehsti University of Medical Sciences.

Go here to read the rest:
Buccal Fat Pad as a Potential Source of Stem Cells for Bone ... - Hindawi

Read More...

Difference Between Adult and Embryonic Stem Cells

December 20th, 2022 12:37 am

The key difference between adult and embryonic stem cells is that adult stem cells are multipotent while embryonic stem cells are pluripotent.

Stem cells are a category of cells with the ability to divide and develop into different types of cells in the body. They are distinguished from the normal cells since they divide and renew themselves over a longer period of time. Moreover, they are unspecialized cells with no specific cellular function in the body. They have the potential to differentiate and become specialized cells in the body such as brain cells, blood cells, and muscle cells. Adult stem cells and embryonic stem cells are two types of stem cells.

1. Overview and Key Difference2. What areAdult Stem Cells3. What are Embryonic Stem Cells4. Similarities Between Adult and Embryonic Stem Cells5. Side by Side Comparison Adult vs Embryonic Stem Cells in Tabular Form6. Summary

Adult stem cells are present in differentiated tissues of the body. These tissues include skeletal muscle, liver, pancreas, brain, eye, dental pulp, skin, bone marrow, blood and lining of the gastrointestinal tract. Moreover, adult stem cells remain in these tissues undifferentiated, with continuous self-renewal and producing identical copies of cells throughout the lifetime of the organism. They undergo differentiation into specialized cells of their tissues of origin when needed.

Figure 01: Adult Stem Cells Repair

Hematopoietic stem cells are a type of adult stem cells present in the bone marrow. They are considered multipotent stem cells as they give rise to different types of blood cells from a single type of cells. Regulated gene expression is responsible for these variations in differentiated cells. It is controlled by special types of transcription factors. Also, stem cells present in the brain are multipotent. They give rise to both muscle and blood cells.

Embryonic stem cells are the undifferentiated cells present in the inner cell mass of the blastocyst a hollow ball of cells developed from the zygote after rapid mitosis. Hence, these stem cells are categorized as stem cells present in the early stages of embryonic development.

Embryonic stem cells are pluripotent. Therefore, they give rise to cells of three germ layers endoderm, ectoderm, and mesoderm except the placenta and umbilical cord. Pluripotency distinguishes embryonic stem cells from adult stem cells.

Figure 02: Embryonic Stem Cells

Embryonic stem cells provide valuable assistance as a renewable resource in the study of diseases and for testing of potential therapeutics and drugs. Under defined conditions, embryonic stem cells possess the ability to divide indefinitely.

Adult stem cells and embryonic stem cells are the two main types of stem cells. The key difference between adult and embryonic stem cells is that adult cells are multipotent as they have a limited ability to differentiate while embryonic stem cells are pluripotent as they have the ability to differentiate into any cell type. Also, a further difference between adult and embryonic stem cells is that the embryonic stem cells can readily grow in cell cultures while the growth of adult stem cells in cell cultures is very challenging.

Moreover, a significant difference between adult and embryonic stem cells is that the adult stem cells are present in adult tissues while embryonic stem cells are present in the early development at the blastocyst stage.

The key difference between adult and embryonic stem cells lies in their potency. That is; the adult stem cells are multipotent while embryonic stem cells are pluripotent. Adult stem cells are present in differentiated tissues of the body such as liver, pancreas, skeletal muscle, etc. Regulated gene expression is responsible for variations in differentiated cells derived from adult stem cells. On the other hand, embryonic stem cells are present in the inner cell mass of the blastocyst. These stem cells give rise to the cells of ectoderm, endoderm, and mesoderm. Furthermore, embryonic stem cells divide indefinitely under defined conditions. This is the summary of the difference between adult and embryonic stem cells.

1. The Adult Stem Cell. National Institutes of Health, U.S. Department of Health and Human Services, Available here.2. Stem Cells. A Closer Look at Stem Cells, Available here.

1. Stemcellheartrepair By US gov -(Public Domain) via Commons Wikimedia2. Human embryonic stem cells only A : Human_embryonic_stem_cells.png: (Images: Nissim Benvenisty)derivative work: Vojtech.dostal (talk) Human_embryonic_stem_cells.png (CC BY 2.5) via Commons Wikimedia

Read the original post:
Difference Between Adult and Embryonic Stem Cells

Read More...

Punctal Plugs – American Academy of Ophthalmology

December 20th, 2022 12:36 am

Many people suffer from dry eye, when their eyes do not make enoughtears or the right quality of tears.Eye drops are often used to treat dry eye. However, some people find that having punctal plugs inserted into their eyes can help make them more comfortable.

Punctal plugs are tiny devices that are placed in the eyes tear ducts (called puncta). Puncta are the tiny openings that drain tears from your eyes. About the size of a grain of rice, the plug stops fluid from draining from the eye. This helps keep the eyes surface moist and comfortable, relieving itchy, burning and red eyes.

Punctal plugs are also called punctum plugs, lacrimal plugs or occluders. Usually they are inserted in the puncta of the upper or lower eyelids, or in both. Another type of plug is placed in a deeper part of the tear duct (the canaliculus).

These are made of a material (such as collagen) that gradually breaks down and is absorbed by the body. These plugs can last in the eye from a few days to months. Temporary plugs are often used to keep the eye moist after having refractive surgery, such as LASIK. They are also used when you want to try out punctal plugs to see if they help relieve your dry eye.

These are made of a longer-lasting medical plastic (such as silicone or acrylic). These plugs are designed to stay in the eye for years. They can be removed by your ophthalmologist if needed.

Another type of semi-permanent punctal plug is placed in a deeper part of the tear duct called the canaliculus. These plugs cannot be seen at all in the eye.

First your eye doctor will examine your eye to figure out the best type and size plug for your needs.

Your doctor may numb your tear ducts with anesthesia. In some cases, you may not need to have your eyes numbed. You may feel some pressure as the punctal plug is placed in your eyelid.

After the plugs are inserted, you are usually able to return to your normal activities right away.

As with any treatment or procedure, punctal plugs can have possible risks and side effects.

The most common side effect is having a scratchy orirritating feeling in the corner of your eye. Many people find this feeling goes away or they simply get used to it.

Other side effects and risks may include the following:

Most people find punctal plugs do not cause any problems. However, side effects can happen. If you feel any eye pain, scratchiness or if you think you have an eye infection, tell your eye doctor right away. They may choose to remove the plugs.

How the plugs are removed depends on which type you have. To remove silicon plugs, your eye doctor will use forceps to gently pull the plugs from the tear duct. Another way to remove these plugs is by flushing them out with a salt water solution. This method forces the plugs out of the tear ducts into the nose or throat.

Plugs that are deeper in the tear duct (in the canaliculus) are removed with surgery.

If artificial tears or other eye drops have not relieved your dry eye symptoms, talk with your ophthalmologist. They may recommend trying punctal plugs.

Go here to see the original:
Punctal Plugs - American Academy of Ophthalmology

Read More...

Spending more time with your kids, grandkidsand their germsmay lower risk of a severe outcome from Covid-19, recent studies show – CNBC

December 20th, 2022 12:33 am

Spending more time with your kids, grandkidsand their germsmay lower risk of a severe outcome from Covid-19, recent studies show  CNBC

Continue reading here:
Spending more time with your kids, grandkidsand their germsmay lower risk of a severe outcome from Covid-19, recent studies show - CNBC

Read More...

What Is Auditory Neuropathy? Causes & Treatment | NIDCD

December 20th, 2022 12:32 am

What is auditory neuropathy?

Auditory neuropathy is a hearing disorder in which the inner ear successfully detects sound, but has a problem with sending sound from the ear to the brain. It can affect people of all ages, from infancy through adulthood. The number of people affected by auditory neuropathy is not known, but current information suggests that auditory neuropathies play a substantial role in hearing impairments and deafness.

When their hearing sensitivity is tested, people with auditory neuropathy may have normal hearing or hearing loss ranging from mild to severe. They always have poor speech-perception abilities, meaning that they have trouble understanding speech clearly. People with auditory neuropathy have greater impairment in speech perception than hearing health experts would predict based upon their degree of hearing loss on a hearing test. For example, a person with auditory neuropathy may be able to hear sounds, but would still have difficulty recognizing spoken words. Sounds may fade in and out or seem out of sync for these individuals.

Researchers report several causes of auditory neuropathy. In some cases, the cause may involve damage to the inner hair cellsspecialized sensory cells in the inner ear that transmit information about sounds through the nervous system to the brain. In other cases, the cause may involve damage to the auditory neurons that transmit sound information from the inner hair cells to the brain. Other possible causes may include inheriting genes with mutations or suffering damage to the auditory system, either of which may result in faulty connections between the inner hair cells and the auditory nerve (the nerve leading from the inner ear to the brain), or damage to the auditory nerve itself. A combination of these problems may occur in some cases.

Outer hair cells help amplify sound vibrations entering the inner ear from the middle ear. When hearing is working normally, the inner hair cells convert these vibrations into electrical signals that travel as nerve impulses to the brain, where the brain interprets the impulses as sound.

Although outer hair cellshair cells next to and more numerous than inner hair cellsare generally more prone to damage than inner hair cells, outer hair cells seem to function normally in people with auditory neuropathy.

There are several ways that children may acquire auditory neuropathy. Some children diagnosed with auditory neuropathy experienced particular health problems before or during birth or as newborns. These problems include inadequate oxygen supply during or prior to birth, premature birth, jaundice, low birth weight, and dietary thiamine deficiency. In addition, some drugs used to treat pregnant women or newborns may damage the babys inner hair cells, causing auditory neuropathy. Adults may also develop auditory neuropathy along with age-related hearing loss.

Auditory neuropathy runs in some families, and in some cases, scientists have identified genes with mutations that compromise the ears ability to transmit sound information to the brain. Thus, inheritance of mutated genes is also a risk factor for auditory neuropathy.

Some people with auditory neuropathy have neurological disorders that also cause problems outside of the hearing system. Examples of such disorders are Charcot-Marie-Tooth syndrome and Friedreichs ataxia.

Health professionalsincluding otolaryngologists (ear, nose, and throat doctors), pediatricians, and audiologistsuse a combination of methods to diagnose auditory neuropathy. These include tests of auditory brainstem response (ABR) and otoacoustic emissions (OAE). The hallmark of auditory neuropathy is an absent or very abnormal ABR reading together with a normal OAE reading. A normal OAE reading is a sign that the outer hair cells are working normally.

An ABR test uses electrodes placed on a persons head and ears to monitor brain wave activity in response to sound. An OAE test uses a small, very sensitive microphone inserted into the ear canal to monitor the faint sounds produced by the outer hair cells in response to auditory stimulation. ABR and OAE testing are painless and can be used for newborn babies and infants as well as older children and adults. Other tests may also be used as part of a comprehensive evaluation of an individuals hearing and speech-perception abilities.

Some newborn babies who have been diagnosed with auditory neuropathy improve and start to hear and speak within a year or two. Other infants stay the same, while some get worse and show signs that the outer hair cells no longer function (abnormal otoacoustic emissions). In people with auditory neuropathy, hearing sensitivity can remain stable, get better or worse, or gradually worsen, depending on the underlying cause.

Researchers are still seeking effective treatments for people with auditory neuropathy. Meanwhile, professionals in the hearing field differ in their opinions about the potential benefits of hearing aids, cochlear implants, and other technologies for people with auditory neuropathy. Some professionals report that hearing aids and personal listening devices such as frequency modulation (FM) systems are helpful for some children and adults with auditory neuropathy. Cochlear implants (electronic devices that compensate for damaged or nonworking parts of the inner ear) may also help some people with auditory neuropathy. No tests are currently available, however, to determine whether an individual with auditory neuropathy might benefit from a hearing aid or cochlear implant.

Debate also continues about the best ways to educate and improve communication skills in infants and children who have hearing impairments such as auditory neuropathy. One approach favors sign language as the childs first language. A second approach encourages the use of listening skillstogether with technologies such as hearing aids and cochlear implantsand spoken language. A combination of these two approaches may also be used. Some health professionals believe it may be especially difficult for children with auditory neuropathy to learn to communicate only through spoken language because their ability to understand speech is often severely impaired. Adults with auditory neuropathy and older children who have already developed spoken language may benefit from learning how to speechread (also known as lip reading).

Scientists have identified genes involved in causing some cases of auditory neuropathy, and are working to identify what goes wrong in the auditory system when a person inherits a mutant gene. Researchers are also continuing to investigate the potential benefits of cochlear implants for children with auditory neuropathy, and are examining why cochlear implants may benefit some people with the condition but not others.

The NIDCD maintains a directory of organizations that provide information on the normal and disordered processes of hearing, balance, taste, smell, voice, speech, and language.

NIDCD Information Clearinghouse1 Communication AvenueBethesda, MD 20892-3456Toll-free voice: (800) 241-1044Toll-free TTY: (800) 241-1055Email: nidcdinfo@nidcd.nih.gov

NIH Pub. No. 03-5343September 2016

Continue reading here:
What Is Auditory Neuropathy? Causes & Treatment | NIDCD

Read More...

Vero Neuropathy and Their Patients Pain Free Success Stories | Paid Content – Local 5 – weareiowa.com

December 20th, 2022 12:32 am

Vero Neuropathy and Their Patients Pain Free Success Stories | Paid Content  Local 5 - weareiowa.com

Here is the original post:
Vero Neuropathy and Their Patients Pain Free Success Stories | Paid Content - Local 5 - weareiowa.com

Read More...

Page 110«..1020..109110111112..120130..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick